Infectious Diseases
Antimicrobial Research
Resistance to drugs is increasing globally. New forecasts from the Global Research on Antimicrobial Resistance (GRAM) Project estimate that bacterial antimicrobial resistance (AMR) will cause 39 million deaths between 2025 and 2050.
AMR is a major global health threat because drug resistance means that bacteria no longer respond to medicines. Treatments for disease can fail, leading people to die from common infections such as pneumonia.
The Wellcome Open Research Connection
Antimicrobial resistance (AMR) is a key focus area for Wellcome Open Research.
As a massive public health threat where low-and middle-income countries shoulder the highest burden of drug-resistant infections, Wellcome is looking to bring innovative solutions to combat infectious disease with collective, evidence-based action.
We are supporting projects worldwide that improve how countries track, share and analyze information about the spread of drug-resistant infections. This research will allow for better understanding about what causes infectious diseases to escalate and what’s being done to develop solutions to control impact.
The Story of ‘Superbugs’ – India
India has a high-density population. Drugs are freely available and when people develop an illness, there can be widespread sharing of drugs without a doctor’s prescription. Over time, there has been an increase in ‘superbugs’, or anti-microbial resistance.
The Indian government has invested in technology campuses where there are incubators, or start-ups, with the intention of fostering faster development of new antibiotics.
Bugworks is a small start-up company based in Bangalore. Early support from the Indian government helped the organization secure funding from the international antibiotic R&D partnership, CARB-X to develop and trial new antibiotics.
For India, the research being undertaken is not only being innovated in India but is helping to solve Indian problems while increasing the chances of treatments becoming available for patients worldwide.
Why Publish with Wellcome Open Research?
Wellcome is a global charitable foundation with a vision of a healthier future for everyone.
It supports bold research and the scientific community as it seeks answers to key health issues.
In the area of Infectious Diseases, urgent action on antimicrobial resistance (AMR) is needed to protect human, animal and environmental health and save millions of lives.
Wellcome seeks research that finds innovative solutions, with the long-term aim of reducing the risk and impact of drug-resistant infections and diseases impacted by environmental change.
Be part of the solution and contribute to improving outcomes to prevent disease escalation.
Five Key Benefits of Publishing with Us
Research transparency:
All research is published freely and openly, including any data used within research, to ensure maximum transparency, reproducibility, and collaboration.Speed of publication:
Peer review is conducted post-publication to ensure new research findings can be shared without delay.No publication charges:
As a Platform for recipients of Wellcome funding, there are no costs to authors for publishing on the Platform.Open peer review:
Peer review is conducted openly to ensure full transparency and enable others to build upon expert guidance.All research outputs welcomed:
All research outputs can be published, from traditional Research Articles to Data Notes to Study Protocols. All results are welcomed, including negative or null results and reanalysis of previous studies with new results.
Publish with Wellcome Open Research Today
Join our mailing list
Be the first to know about calls for papers, new content, researcher stories and more. Sign up to the Wellcome Open Research mailing list today.